GSK sinks to bottom of the FTSE on Zantac ruling
Shares in GSK (GSK) fell 10% to the bottom of the FTSE 100 after a Delaware judge on Friday (31 May) allowed more than 70,000 Zantac cases, which claim the discontinued heartburn drug caused cancer, to proceed to trial.
French pharmaceutical firm Sanofi (SAN:EPA), which is also embroiled in the Zantac litigation, saw its shares cheapen 2% to €88.9 on the news.
GSK said it will immediately see...